Online inquiry

IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6940MR)

This product GTTS-WQ6940MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA), Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6940MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11883MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ15738MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ4388MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ12333MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ1032MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ9546MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ13291MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ9636MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW